{
    "hands_on_practices": [
        {
            "introduction": "The management of unknown primary squamous cell carcinoma hinges on a rigorous diagnostic process. While imaging modalities like Positron Emission Tomography–Computed Tomography ($PET-CT$) are crucial for attempting to locate a primary tumor, their interpretation requires more than a simple binary assessment. This exercise  provides a practical application of Bayes' theorem to quantify the true diagnostic power of a positive $PET-CT$ scan. By deriving and calculating the Positive Predictive Value ($PPV$), you will learn how to translate test characteristics like sensitivity ($s$) and specificity ($t$) into a clinically meaningful post-test probability, directly informing patient counseling and subsequent diagnostic steps.",
            "id": "5081792",
            "problem": "A patient presents with metastatic cervical lymph node involvement confirmed as squamous cell carcinoma on fine-needle aspiration, but comprehensive endoscopic evaluation and contrast-enhanced cross-sectional imaging fail to identify a mucosal primary, constituting the scenario of unknown primary squamous cell carcinoma in the head and neck. The multidisciplinary team considers Positron Emission Tomography–Computed Tomography ($PET-CT$) to localize an occult mucosal primary. Let the test characteristic definitions be as follows: sensitivity $s$ is the probability of a positive test given disease, specificity $t$ is the probability of a negative test given no disease, and pretest probability $p$ is the probability that a true, $PET-CT$-detectable mucosal primary exists prior to testing, given the clinical workup to date. Using the foundational definitions of sensitivity, specificity, and Bayes’ theorem on conditional probabilities, derive from first principles the expression for the positive predictive value, defined as the probability that disease is present given a positive test, and then compute its value for $PET-CT$ with $s=0.88$, $t=0.85$, and $p=0.35$. Express your final answer as a decimal and round to four significant figures. Finally, justify the clinical utility of this value for decision-making in unknown primary squamous cell carcinoma of the head and neck, including implications for targeted biopsies and treatment planning based on the computed probability.",
            "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n**Step 1: Extract Givens**\n- Clinical scenario: Unknown primary squamous cell carcinoma of the head and neck.\n- Diagnostic test: Positron Emission Tomography–Computed Tomography ($PET-CT$).\n- Sensitivity: $s$, the probability of a positive test given disease.\n- Specificity: $t$, the probability of a negative test given no disease.\n- Pretest probability: $p$, the probability that a true, $PET-CT$-detectable mucosal primary exists.\n- Positive Predictive Value (PPV): The probability that disease is present given a positive test.\n- Numerical values: $s=0.88$, $t=0.85$, $p=0.35$.\n- Task 1: Derive the expression for PPV from first principles using Bayes' theorem.\n- Task 2: Compute the numerical value for PPV, rounded to four significant figures.\n- Task 3: Justify the clinical utility of the computed value.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is based on standard principles of biostatistics and their application in clinical medicine, specifically in the diagnostic workup of cancer. The definitions of sensitivity, specificity, pretest probability, and positive predictive value are standard. Bayes' theorem is the correct mathematical framework for relating these quantities. The scenario described is a common and challenging clinical problem in otorhinolaryngology, and the use of $PET-CT$ is a standard diagnostic step. The provided numerical values for sensitivity and specificity are realistic for the performance of modern $PET-CT$ in this context. The pretest probability is a reasonable estimate for a patient population that has already undergone negative standard workup. The problem is self-contained, scientifically sound, and well-posed. There are no contradictions, ambiguities, or factual errors.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid. A full solution will be provided.\n\n**Derivation of Positive Predictive Value (PPV)**\n\nLet $D$ be the event that the disease (a detectable mucosal primary tumor) is present, and $D^c$ be the event that the disease is not present. Let $T^+$ be the event of a positive test result from the $PET-CT$ scan, and $T^-$ be the event of a negative test result.\n\nThe given probabilities can be expressed in conditional probability notation:\n- Pretest probability of disease: $P(D) = p$\n- Probability of no disease: $P(D^c) = 1 - P(D) = 1 - p$\n- Sensitivity: The probability of a positive test given that the disease is present. $P(T^+|D) = s$\n- Specificity: The probability of a negative test given that the disease is not present. $P(T^-|D^c) = t$\n\nFrom the definition of specificity, we can deduce the probability of a positive test in a patient without the disease (a false positive). This is the complement of specificity:\n$P(T^+|D^c) = 1 - P(T^-|D^c) = 1 - t$\n\nThe Positive Predictive Value (PPV) is defined as the probability that the disease is present given a positive test result, which is written as $P(D|T^+)$.\n\nAccording to Bayes' theorem, this conditional probability is given by:\n$$P(D|T^+) = \\frac{P(T^+|D)P(D)}{P(T^+)}$$\n\nThe denominator, $P(T^+)$, represents the total probability of obtaining a positive test result. It can be calculated using the law of total probability, which considers both ways a positive result can occur: a true positive (disease is present and the test is positive) and a false positive (disease is absent but the test is positive).\n$$P(T^+) = P(T^+ \\cap D) + P(T^+ \\cap D^c)$$\nUsing the definition of conditional probability, $P(A \\cap B) = P(A|B)P(B)$, we can expand this to:\n$$P(T^+) = P(T^+|D)P(D) + P(T^+|D^c)P(D^c)$$\n\nSubstituting the terms $s$, $t$, and $p$ into this expression:\n$$P(T^+) = (s)(p) + (1-t)(1-p)$$\n\nNow, we substitute this expanded expression for $P(T^+)$ back into the Bayes' theorem formula for PPV:\n$$\\text{PPV} = P(D|T^+) = \\frac{P(T^+|D)P(D)}{P(T^+|D)P(D) + P(T^+|D^c)P(D^c)}$$\nThis yields the final expression for PPV in terms of sensitivity $s$, specificity $t$, and pretest probability $p$:\n$$\\text{PPV} = \\frac{s \\cdot p}{s \\cdot p + (1-t)(1-p)}$$\nThis completes the derivation from first principles.\n\n**Computation of PPV**\n\nWe are given the following values:\n- $s = 0.88$\n- $t = 0.85$\n- $p = 0.35$\n\nFirst, we calculate the terms needed for the formula:\n- $1 - t = 1 - 0.85 = 0.15$\n- $1 - p = 1 - 0.35 = 0.65$\n\nNow, we compute the numerator and denominator of the PPV expression.\n- Numerator: $s \\cdot p = 0.88 \\times 0.35 = 0.308$\n- Denominator term 1 (true positives): $s \\cdot p = 0.308$\n- Denominator term 2 (false positives): $(1-t)(1-p) = 0.15 \\times 0.65 = 0.0975$\n- Total denominator (total probability of a positive test): $P(T^+) = 0.308 + 0.0975 = 0.4055$\n\nFinally, we compute the PPV:\n$$\\text{PPV} = \\frac{0.308}{0.4055} \\approx 0.7595561035...$$\n\nRounding the result to four significant figures, we get:\n$$\\text{PPV} \\approx 0.7596$$\n\n**Justification of Clinical Utility**\n\nThe computed Positive Predictive Value of approximately $0.7596$ has significant clinical utility in the management of unknown primary squamous cell carcinoma of the head and neck.\n\n1.  **Enhanced Diagnostic Certainty**: The pretest probability ($p$) of finding a mucosal primary was $0.35$, or $35\\%$. After a positive $PET-CT$ scan, the post-test probability (the PPV) rises to approximately $0.76$, or $76\\%$. This represents a substantial increase in the certainty that a primary tumor is located at the site of $PET-CT$ avidity. This more than doubles the likelihood of disease being present at the identified \"hot spot\".\n\n2.  **Guidance for Further Investigation**: A PPV of $76\\%$ provides a strong justification for proceeding with more invasive diagnostic procedures. A surgeon can now perform targeted biopsies of the PET-positive area (e.g., via panendoscopy and direct visualization of the base of tongue, tonsils, or nasopharynx) with a much higher confidence of obtaining a diagnostic tissue sample. This increases the diagnostic yield of the biopsy procedure and reduces the likelihood of performing a non-contributory surgery, thereby minimizing patient morbidity and healthcare costs.\n\n3.  **Informing Treatment Planning**: The localization of a primary tumor is critical for optimal treatment planning.\n    - If a targeted biopsy confirms the primary site, the radiation oncologist can design a more focused radiotherapy plan that precisely targets the confirmed primary and the involved cervical nodes. This can allow for dose de-escalation or sparing of other mucosal sites, reducing the severe side effects (mucositis, xerostomia, dysphagia) associated with irradiating the entire pharyngeal axis, which is often done when the primary remains unidentified.\n    - Even if a targeted biopsy is negative despite a positive $PET-CT$, the high PPV of $76\\%$ may influence the multidisciplinary team to consider the PET-positive region a high-risk subsite. The radiation oncologist might still choose to include this area within the high-dose radiation field, treating it as the presumptive primary site, which is a more targeted approach than treating all potential mucosal sites empirically.\n\nIn summary, the PPV transforms a probability of $0.35$ (a significant possibility) into a probability of $0.76$ (a strong likelihood). This quantitative shift provides clinicians with the confidence needed to guide invasive diagnostic procedures and tailor patient-specific treatment, aiming to improve diagnostic accuracy and optimize therapeutic outcomes while minimizing treatment-related toxicity.",
            "answer": "$$ \\boxed{0.7596} $$"
        },
        {
            "introduction": "Beyond imaging, molecular biomarkers from the metastatic node offer powerful clues to the site of origin. However, these markers can sometimes present a conflicting picture or clash with negative findings from initial examinations. This practice  challenges you to act as a clinical detective, using foundational principles of tumor virology ($HPV$ and $EBV$) to resolve these conflicts. You will learn to identify which biomarker constellations provide a strong enough signal to justify abandoning the 'unknown primary' label and proceeding with targeted, and sometimes invasive, re-biopsies of cryptic mucosal sites like the oropharynx or nasopharynx.",
            "id": "5081788",
            "problem": "A patient presents with metastatic cervical squamous cell carcinoma with no mucosal primary identified after a standard work-up that included contrast-enhanced cross-sectional imaging, whole-body Positron Emission Tomography/Computed Tomography ($PET/CT$), and panendoscopy with directed biopsies. The question is when viral biomarker information from the nodal metastasis should prompt abandoning the provisional “unknown primary” label and proceeding to targeted re-biopsy of specific mucosal sites.\n\nUse the following foundational bases appropriate to head and neck oncology: (i) Human Papillomavirus (HPV) drives a large fraction of oropharyngeal squamous cell carcinomas (OPSCC) arising in lymphoepithelial crypt epithelium of the palatine and lingual tonsils; (ii) cyclin-dependent kinase inhibitor $2\\mathrm{A}$ ($p16$) immunohistochemistry is a sensitive, but not perfectly specific, surrogate for transcriptionally active HPV in OPSCC; (iii) direct detection of high-risk HPV $E6/E7$ messenger $RNA$ by in situ hybridization indicates viral transcriptional activity and is more specific than $DNA$ polymerase chain reaction for causal HPV status; (iv) Epstein-Barr virus (EBV)-associated non-keratinizing carcinomas arise predominantly in the nasopharyngeal mucosa; (v) Epstein-Barr virus-encoded $RNA$ in situ hybridization ($EBER-ISH$) in tumor cells is highly specific for EBV-driven nasopharyngeal carcinoma; and (vi) small primaries in crypt-rich mucosa can be missed on inspection and superficial biopsies and may require en bloc sampling, such as bilateral palatine tonsillectomy or transoral lingual tonsillectomy (base-of-tongue mucosectomy), and targeted nasopharyngeal biopsies from the fossa of Rosenmüller.\n\nWhich of the following scenarios correctly identifies discordant or conflicting viral marker constellations that should prompt reconsideration of the “unknown primary” label and targeted re-biopsy of the stated mucosal site(s)?\n\nA. Nodal metastasis shows strong, diffuse $p16$ immunohistochemistry (staining $\\geq 70\\%$ of tumor cells) but is negative for high-risk HPV $E6/E7$ $RNA$ by in situ hybridization; $PET/CT$ is negative and initial panendoscopy with directed biopsies is negative. Proceed with bilateral palatine tonsillectomy and transoral lingual tonsillectomy (base-of-tongue mucosectomy).\n\nB. Nodal metastasis is positive by $EBER-ISH$; $PET/CT$ and flexible nasoendoscopy are negative. Proceed with targeted nasopharyngeal biopsies including the fossa of Rosenmüller and posterior nasopharyngeal wall.\n\nC. Nodal metastasis is $p16$ negative but low-copy high-risk HPV $DNA$ is detected by polymerase chain reaction; morphology is non-keratinizing. Prior oropharyngeal mucosal sampling was negative. Maintain the “unknown primary” label and avoid further oropharyngeal re-biopsy.\n\nD. Nodal metastasis is $EBER-ISH$ negative, but serum EBV viral capsid antigen $IgA$ titer is elevated; $PET/CT$ and nasoendoscopy are negative. Proceed with targeted nasopharyngeal biopsies.\n\nE. Nodal metastasis shows dual positivity: strong, diffuse $p16$ and $EBER-ISH$ both positive in tumor cells; endoscopy is negative and $PET/CT$ shows only low, symmetric tonsillar uptake. Proceed with combined re-biopsy strategy: bilateral palatine tonsillectomy plus transoral lingual tonsillectomy and targeted nasopharyngeal biopsies.\n\nSelect all that apply.",
            "solution": "The central task is to identify which viral marker scenarios create a conflict or discordance that correctly prompts a specific targeted re-biopsy to find a cryptic primary carcinoma, based on the provided foundational principles.\n\nA \"discordant or conflicting\" constellation arises when markers provide ambiguous or contradictory information, or when a strong marker result conflicts with negative imaging and endoscopic findings.\n\n**A. Nodal metastasis shows strong, diffuse $p16$ immunohistochemistry... but is negative for high-risk HPV $E6/E7$ $RNA$... Proceed with... tonsillectomy...**\n\n*   **Analysis:** This represents a classic conflict. Strong $p16$ positivity is a sensitive indicator for an HPV-driven OPSCC (Principles i, ii), strongly suggesting an oropharyngeal primary. The negative result on the more specific HPV $E6/E7$ $mRNA$ test (Principle iii) creates a discordance. However, in the clinical context of an unknown primary, the high sensitivity of $p16$ often drives the decision. The high likelihood of a cryptic oropharyngeal primary, despite the negative confirmatory test and negative workup, justifies the proposed action of en bloc sampling of the oropharyngeal lymphoid tissue (Principle vi). This scenario correctly identifies a conflicting marker profile that prompts a targeted re-biopsy.\n*   **Verdict:** **Correct**.\n\n**B. Nodal metastasis is positive by $EBER-ISH$; $PET/CT$ and... nasoendoscopy are negative. Proceed with targeted nasopharyngeal biopsies...**\n\n*   **Analysis:** This scenario presents a conflict between a highly specific tumor marker and a negative initial workup. $EBER-ISH$ positivity is highly specific for an EBV-driven carcinoma (Principle v), which points overwhelmingly to a nasopharyngeal primary (Principle iv). The fact that imaging and endoscopy are negative is the very definition of an occult primary, and Principle (vi) explains that such tumors can be hidden. The strong, specific $EBER-ISH$ result provides a clear direction, overriding the negative work-up and correctly prompting a targeted re-biopsy of the most likely site.\n*   **Verdict:** **Correct**.\n\n**C. Nodal metastasis is $p16$ negative but low-copy high-risk HPV $DNA$ is detected... Maintain the “unknown primary” label and avoid further... re-biopsy.**\n\n*   **Analysis:** The question asks for scenarios that *prompt* re-biopsy. The action proposed in this option is to *avoid* re-biopsy. Therefore, this option fails to meet the fundamental requirement of the question. The clinical reasoning itself is sound (a negative sensitive screen, $p16$, paired with a positive non-specific test, low-copy $DNA$ $PCR$, provides weak evidence), but the proposed action is the opposite of what is being asked for.\n*   **Verdict:** **Incorrect**.\n\n**D. Nodal metastasis is $EBER-ISH$ negative, but serum EBV... $IgA$ titer is elevated... Proceed with targeted nasopharyngeal biopsies.**\n\n*   **Analysis:** This scenario presents a conflict between a definitive tissue-based test and a non-specific systemic test. The metastasis being $EBER-ISH$ negative is extremely strong evidence against the tumor being EBV-driven (Principle v). Serum EBV serologies can be elevated for other reasons and lack the specificity of direct viral detection within tumor cells. Clinical reasoning dictates that the definitive negative finding in the tumor tissue ($EBER-ISH$ negative) takes precedence over the non-specific serological finding. Proceeding with nasopharyngeal biopsies is not justified.\n*   **Verdict:** **Incorrect**.\n\n**E. Nodal metastasis shows dual positivity: strong, diffuse $p16$ and $EBER-ISH$ both positive... Proceed with combined re-biopsy strategy...**\n\n*   **Analysis:** This is a highly conflicting scenario. Strong $p16$ positivity points towards an oropharyngeal primary (Principles i, ii). Concurrently, $EBER-ISH$ positivity points towards a nasopharyngeal primary (Principles iv, v). This rare dual positivity creates a significant diagnostic dilemma, as there is strong evidence for two distinct primary sites. The low, symmetric tonsillar uptake on $PET/CT$ is a non-specific finding. Given the ambiguity, the most logical and thorough approach is to investigate both high-probability sites. The proposed combined re-biopsy strategy directly addresses the conflict and is a rational course of action.\n*   **Verdict:** **Correct**.",
            "answer": "$$\\boxed{ABE}$$"
        },
        {
            "introduction": "Once the diagnostic workup is complete, the focus shifts to selecting the optimal treatment strategy, often involving a difficult trade-off between maximizing disease control and minimizing long-term toxicity. This final exercise  introduces you to the principles of medical decision analysis, a formal method for comparing complex treatment pathways. By calculating an expected utility for different strategies and determining a 'toxicity-aversion' threshold ($\\alpha^{\\ast}$), you will develop the skills to quantitatively frame clinical dilemmas and facilitate shared decision-making, tailoring treatment to both the oncologic scenario and the patient's personal values.",
            "id": "5081822",
            "problem": "A patient presents with an unknown primary squamous cell carcinoma of the head and neck, with cervical metastases and negative conventional imaging. Two definitive management strategies are being considered: (A) panmucosal irradiation of the pharyngeal mucosa with bilateral neck coverage and (B) Transoral Robotic Surgery (TORS)-directed mucosal sampling followed by tailored radiotherapy fields contingent on whether a mucosal primary is identified. Assume the following scientifically plausible and internally consistent probabilities derived from institutional data in Human Papillomavirus (HPV)-associated disease cohorts:\n\n- For strategy (A), the probability of achieving locoregional disease control is $p_{c,A} = 0.90$, and the probability of experiencing grade $3+$ late toxicity (per Common Terminology Criteria for Adverse Events (CTCAE)) is $p_{t,A} = 0.38$.\n- For strategy (B), the probability that TORS-directed sampling identifies a primary is $p_{d} = 0.60$. Conditional on identification, the probability of achieving locoregional disease control with tailored fields is $p_{c, \\mathrm{tail}} = 0.92$, and the probability of grade $3+$ late toxicity is $p_{t, \\mathrm{tail}} = 0.20$. Conditional on non-identification, the probability of achieving locoregional disease control with fallback adjuvant coverage is $p_{c, \\mathrm{fall}} = 0.86$, and the probability of grade $3+$ late toxicity is $p_{t, \\mathrm{fall}} = 0.42$.\n\nAdopt a decision-analytic expected utility framework grounded in classical expected utility theory. Let the utility of a strategy be modeled as the weighted sum of the probability of locoregional control and the disutility of toxicity, with independent contributions and a linear trade-off parameter. Specifically, for any strategy with locoregional control probability $p_{c}$ and grade $3+$ late toxicity probability $p_{t}$, define the expected utility as\n$$\nU = w_{c} \\, p_{c} - \\alpha \\, p_{t},\n$$\nwhere $w_{c} > 0$ is the utility weight for disease control and $\\alpha \\geq 0$ is the toxicity-aversion coefficient. Without loss of generality, normalize $w_{c} = 1$.\n\nAssuming independence of locoregional control and grade $3+$ late toxicity events conditional on strategy choice, and applying the law of total probability to strategy (B), derive the toxicity-aversion threshold $\\alpha^{\\ast}$ such that the expected utilities of strategies (A) and (B) are equal. Round your final numerical value for $\\alpha^{\\ast}$ to four significant figures and report it without units.",
            "solution": "The problem is subjected to validation before a solution is attempted.\n\n**Step 1: Extract Givens**\n- Strategy (A):\n  - Probability of locoregional control: $p_{c,A} = 0.90$\n  - Probability of grade $3+$ late toxicity: $p_{t,A} = 0.38$\n- Strategy (B):\n  - Probability of TORS identifying a primary: $p_{d} = 0.60$\n  - Conditional probabilities if primary is identified:\n    - Control probability: $p_{c, \\mathrm{tail}} = 0.92$\n    - Toxicity probability: $p_{t, \\mathrm{tail}} = 0.20$\n  - Conditional probabilities if primary is not identified:\n    - Control probability: $p_{c, \\mathrm{fall}} = 0.86$\n    - Toxicity probability: $p_{t, \\mathrm{fall}} = 0.42$\n- Expected Utility Function: $U = w_{c} \\, p_{c} - \\alpha \\, p_{t}$\n- Normalization and Constraints: $w_{c} = 1$, $\\alpha \\geq 0$\n- Objective: Find the toxicity-aversion threshold $\\alpha^{\\ast}$ such that the expected utilities of strategies (A) and (B) are equal.\n- Assumption: Independence of locoregional control and toxicity events, conditional on strategy.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, employing standard concepts from medical decision analysis (expected utility theory), radiation oncology (locoregional control, toxicity), and surgical oncology (TORS). The scenario presented is a realistic and significant clinical dilemma in the management of head and neck cancer. The language is objective and precise. The problem is well-posed, providing all necessary data and definitions to arrive at a unique solution for $\\alpha^{\\ast}$. The provided probabilities are internally consistent and plausible within the clinical context. The problem does not violate any of the invalidity criteria.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid. A solution will be derived.\n\nThe expected utility, $U$, for a given strategy with locoregional control probability $p_c$ and toxicity probability $p_t$ is defined as:\n$$\nU = w_{c} \\, p_{c} - \\alpha \\, p_{t}\n$$\nWith the normalization $w_{c} = 1$, this simplifies to:\n$$\nU = p_{c} - \\alpha \\, p_{t}\n$$\n\nFirst, we define the expected utility for strategy (A), denoted $U_A$. Using the given probabilities for strategy (A), $p_{c,A} = 0.90$ and $p_{t,A} = 0.38$, we have:\n$$\nU_A = p_{c,A} - \\alpha \\, p_{t,A} = 0.90 - 0.38\\alpha\n$$\n\nNext, we must determine the overall probabilities of control and toxicity for strategy (B), which involves two possible outcomes: identification of the primary tumor via TORS-directed sampling (event $D$) or non-identification (event $D^c$). The problem states the probability of identification is $p_d = P(D) = 0.60$. Therefore, the probability of non-identification is $P(D^c) = 1 - p_d = 1 - 0.60 = 0.40$.\n\nWe use the law of total probability to find the overall probability of locoregional control for strategy (B), $p_{c,B}$:\n$$\np_{c,B} = P(\\text{control}|D)P(D) + P(\\text{control}|D^c)P(D^c)\n$$\nSubstituting the given conditional probabilities, $p_{c, \\mathrm{tail}} = 0.92$ and $p_{c, \\mathrm{fall}} = 0.86$:\n$$\np_{c,B} = p_{c, \\mathrm{tail}} \\, p_d + p_{c, \\mathrm{fall}} \\, (1 - p_d)\n$$\n$$\np_{c,B} = (0.92)(0.60) + (0.86)(0.40) = 0.552 + 0.344 = 0.896\n$$\n\nSimilarly, we use the law of total probability to find the overall probability of grade $3+$ late toxicity for strategy (B), $p_{t,B}$:\n$$\np_{t,B} = P(\\text{toxicity}|D)P(D) + P(\\text{toxicity}|D^c)P(D^c)\n$$\nSubstituting the given conditional probabilities, $p_{t, \\mathrm{tail}} = 0.20$ and $p_{t, \\mathrm{fall}} = 0.42$:\n$$\np_{t,B} = p_{t, \\mathrm{tail}} \\, p_d + p_{t, \\mathrm{fall}} \\, (1 - p_d)\n$$\n$$\np_{t,B} = (0.20)(0.60) + (0.42)(0.40) = 0.120 + 0.168 = 0.288\n$$\n\nNow we can define the expected utility for strategy (B), $U_B$, using these calculated overall probabilities:\n$$\nU_B = p_{c,B} - \\alpha \\, p_{t,B} = 0.896 - 0.288\\alpha\n$$\n\nThe toxicity-aversion threshold, $\\alpha^{\\ast}$, is the value of $\\alpha$ at which the expected utilities of the two strategies are equal, i.e., $U_A = U_B$.\n$$\np_{c,A} - \\alpha^{\\ast} \\, p_{t,A} = p_{c,B} - \\alpha^{\\ast} \\, p_{t,B}\n$$\nWe rearrange this equation to solve for $\\alpha^{\\ast}$:\n$$\n\\alpha^{\\ast} \\, p_{t,B} - \\alpha^{\\ast} \\, p_{t,A} = p_{c,B} - p_{c,A}\n$$\n$$\n\\alpha^{\\ast} (p_{t,B} - p_{t,A}) = p_{c,B} - p_{c,A}\n$$\n$$\n\\alpha^{\\ast} = \\frac{p_{c,B} - p_{c,A}}{p_{t,B} - p_{t,A}}\n$$\nThis equation represents the ratio of the incremental gain in locoregional control probability to the incremental gain in toxicity probability when moving from strategy A to B. Here, both are negative, representing a trade-off.\n\nSubstituting the numerical values:\n$$\n\\alpha^{\\ast} = \\frac{0.896 - 0.90}{0.288 - 0.38} = \\frac{-0.004}{-0.092} = \\frac{4}{92} = \\frac{1}{23}\n$$\nCalculating the numerical value:\n$$\n\\alpha^{\\ast} = \\frac{1}{23} \\approx 0.04347826...\n$$\nRounding to four significant figures as required by the problem statement, we obtain:\n$$\n\\alpha^{\\ast} \\approx 0.04348\n$$\nThis value represents the indifference point. For a decision-maker whose toxicity aversion $\\alpha$ is greater than $\\alpha^{\\ast}$, strategy (B) is preferred due to its lower overall toxicity. For a decision-maker with $\\alpha < \\alpha^{\\ast}$, strategy (A) is preferred due to its slightly higher control probability.",
            "answer": "$$\n\\boxed{0.04348}\n$$"
        }
    ]
}